DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Active, not recruiting · NCT05680922 · Registry updated 2026-03-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | pulmonary large cell neuroendocrine carcinoma | Active, not recruiting | Phase 1 | 2026-03-24 | NCT05680922 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Legend Biotech USA Inc | 2 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 5 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| University of Kentucky - Markey Cancer Center | Lexington | United States | 3 |